Standard BioTools
LAB
98 hedge funds and large institutions have $218M invested in Standard BioTools in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 13 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
1% more funds holding
Funds holding: 97 → 98 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
11% less capital invested
Capital invested by funds: $246M → $218M (-$27.8M)
64% less call options, than puts
Call options by funds: $126K | Put options by funds: $349K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$7.25M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.51M |
| 3 |
Neuberger Berman Group
New York
|
+$3.03M |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
+$2.36M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$16M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.32M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.83M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.35M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$489K |
LAB Hedge Fund Activity: Q3 2016 in Review
98 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2016, worth a combined $218M — down 11% from $246M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LAB positions and 13 closed out — a net gain of 1 holder — while 34 added to existing stakes and 21 trimmed.
The largest buyer was Levin Capital Strategies, adding an estimated $7.25M. The largest seller was Columbia Wanger Asset Management, exiting entirely with an estimated $16M sold.
- 98 institutional investors held Standard BioTools (LAB) as of Q3 2016, up from 97 in Q2 2016.
- Funds reported $218M of Standard BioTools stock for Q3 2016, down 11% quarter-over-quarter.
- 14 funds opened new Standard BioTools positions in Q3 2016 and 13 closed out, a net change of +1 holder.
- The largest Standard BioTools buyer in Q3 2016 was Levin Capital Strategies, an estimated $7.25M added.
- The largest Standard BioTools seller in Q3 2016 was Columbia Wanger Asset Management, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2016.